New balloon device shows promise in clearing hardened heart blockages
NCT ID NCT06358508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a very small balloon catheter (Sapphire 3) in 170 people with severely blocked heart arteries (chronic total occlusions). The balloon was used to open the blockage before placing a stent. The main goal was to see if the device could be safely delivered, inflated, and removed without causing serious damage. Results focused on immediate success and safety during the hospital stay.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
170 people
The number who actually took part.
- Started
-
Nov 2024
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Clinical Inclusion Criteria: 1. Subject is ≥ 18 years of age. 2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedures. 3. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study. 4. Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization with planned stent placement during this index procedure. Angiographic Inclusion Criteria 5. Subject must have at least one de novo or restenotic lesion in native coronary arteries with Thrombolysis In Myocardial Infarction (TIMI) flow grade of 0 or 1 and is estimated to be at least 3 months in duration by clinical, angiographic, or electrocardiographic criteria. 6. A maximum of two lesions, including at least one target lesion, in up to two coronary arteries. 7. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success by visual assessment. 8. The Target lesion is intended for stent placement during this index procedure. Clinical Exclusion Criteria: 1. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated. 2. Evidence of acute myocardial infarction (MI) within 72 hours prior to the intended treatment defined as CK-MB or troponin greater than 1X the upper limit of normal (ULN). 3. Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure. 4. Planned or actual target lesion treatment prior to the use of the Study Device with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure. 5. A serum creatinine level \> 2.0 mg/dl within seven days prior to index procedure. 6. Cerebrovascular accident (CVA) within the past 6 months. 7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months. 8. Subject has a known left ventricular ejection fraction (LVEF) \<30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary). Angiographic Exclusion Criteria 9. More than two lesions requiring treatment. 10. Unprotected left main coronary artery disease. (Greater than 50% diameter stenosis). 11. Coronary artery spasm of the target vessel in the absence of a significant stenosis. 12. Target lesion with angiographic presence of probable or definite thrombus of TIMI thrombus grade 3 or 4. 13. By visual estimation, target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch \>2.25 mm in diameter. 14. Previous coronary interventional procedure of any kind within the 30 days prior to the procedure in the target vessel. 15. Target vessel with a patent bypass graft from prior coronary bypass surgery. 16. Previous stenting (drug-eluting or bare metal) in the target vessel unless all the following conditions are met: * It has been at least 9 months since the previous stenting. * That target lesion is at least 15 mm away from the previously placed stent. Total occlusions involving an in-stent segment are excluded. * The previously stented segment (stent plus 5 mm on either side) has no more than 40% diameter stenosis. 17. Non-target lesion to be treated during the index procedure meets any of the following criteria: * Located within a bypass graft (venous or arterial) * Left main location * Chronic total occlusion (CTO) * Is moderately to severely calcified. * Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent) * Treatment not deemed a clinical angiographic success
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arteriosclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlanta VA Health Care System
Decatur, Georgia, 30033, United States
-
Brigham and Women's Hospital Heart and Vascular Center
Boston, Massachusetts, 02115, United States
-
Emory St. Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Clinico Universitario de Valladolid
Valladolid, 47003, Spain
-
Hospital Universitari de Bellvitge
Barcelona, 08907, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, 55407, United States
-
Piedmont Heart Institute
Atlanta, Georgia, 30309, United States
-
Stanford Health Care
Stanford, California, 94305, United States
-
Torrance Memorial Medical Center
Torrance, California, 90505, United States
-
University of Washington
Seattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heart stent patients go home in 6 hours?
- Could monthly texts and automatic risk scores stop heart attacks before they start?
- Can AI read heart scans to predict the next heart attack?
- Can a new drug cool the hidden inflammation that fuels heart disease?
- New CT scanner aims to cut unnecessary heart procedures
- Can a nurse and a neighbor help tame chronic disease?